Legend Biotech (LEGN) Announces Proposed $300M Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/9/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- Atlassian results seen as 'game changer' for AI kills software worries
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Legend Biotech (LEGN) Prices 7.5M Share Offering at $40/sh
December 16, 2021 9:19 AM ESTLegend Biotech Corporation (NASDAQ: LEGN), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that it has priced an underwritten public offering of 7,500,000 American depositary shares (ADSs), each representing two ordinary shares, at a public offering price of $40.00 per ADS, for total gross proceeds of approximately $300.0 million. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being... More
Legend Biotech (LEGN) Presents Two-Year Analysis of CARTITUDE-1 Showing Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Mye
December 13, 2021 9:04 AM ESTLegend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today new and updated results from the CARTITUDE clinical development program studying ciltacabtagene autoleucel (cilta-cel) in the treatment of multiple myeloma, which were presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. Cilta-cel is an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy being studied as a one-time treatment for multiple myeloma.
CARTITUDE-1 Data Continues to Support the Potential of Cilta-cel
In an... More
